This site is intended for health professionals only
Content funded and provided by GSK
For healthcare professionals only
Prescribing information is available via a link at the bottom of the page
Anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD1.
In a post-hoc, pooled analysis of 3 RCTs at 24 weeks in patients not on maintenance therapy (for ≥ 30 days before screening),2,3 Anoro demonstrated a 2.4x greater lung function improvement vs tiotropium HandiHaler with an extra 146mL improvement in trough FEV1.*2,3
Anoro was also well tolerated and demonstrated a safety profile comparable to tiotropium HandiHaler.2
Based on a pooled, post hoc subgroup analysis of patients not on maintenance therapy for ≥ 30 days before screening from three 24-week randomised, active-controlled, multicentre, parallel-group studies. Primary endpoint: trough FEV1 on Day 169.
FEV1, forced expiratory volume in one second; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LS, least squares; MCID, minimal clinically important difference.
In an 8-week open-label crossover study in patients not on maintenance therapy (for ≥ 2 weeks prior to randomisation), Anoro demonstrated a 1.4X superior lung function improvement vs. Spiolto Respimat with an extra 52mL improvement in trough FEV1.4
Anoro also reduced rescue medication use by an extra 38% compared with Spiolto (Difference: 0.25 puffs/day).4
Anoro was well tolerated and demonstrated a safety profile comparable to Spiolto Respimat.4
An 8-week, randomised, open-label, assessor-blind, two-period crossover study in symptomatic patients with moderate COPD (post-bronchodilator FEV1 ≤ 70% and ≥50% of predicted value and mMRC score of ≥ 2) and who were not on maintenance therapy for ≥ 2 weeks prior to randomisation or using inhaled ICS ≥ 30 days before screening.
CI, Confidence interval; FEV1, forced expiratory volume in one second; ICS, inhaled corticosteroid; ITT, intent-to-treat; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; LS, least squares; MCID, minimal clinically important difference; mMRC, modified Medical Research Council.
Anoro also comes in the easy to use Ellipta inhaler. Significantly fewer COPD patients using the Ellipta inhaler made critical errors compared with other commonly used inhalers (Accuhaler, MDI, Turbohaler, HandiHaler, Breezhaler), after reading the patient information leaflet, a randomised, cross-over, open-label study has shown.7
A critical error is defined as inhaler usage likely to result in no, or minimal, medication being inhaled. The key results included:
MDI, metered dose inhaler.
Find out more about the Ellipta and how it could benefit COPD patients here.
Adverse events should be reported. Reporting forms and information can be found
at yellowcard.mhra.gov.uk or search for MHRA Yellow card in the Google Play or Apple App store.
Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
PM-GB-UCV-WCNT-200008 V2.0 | August 2020
© 2020 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.
Anoro Ellipta was developed in collaboration with Innoviva.